Microbiome, a new dimension in cancer research
Editorial

Microbiome, a new dimension in cancer research

Antonio Galvao Neto1, Azore-Dee Bradshaw1, Zhiheng Pei2,3

1Department of Pathology, 2Departments of Medicine and Pathology, New York University School of Medicine, New York, NY, USA; 3Department of Veterans Affairs New York Harbor Healthcare System, New York, NY, USA

Correspondence to: Zhiheng Pei, MD, PhD, FASCP. Department of Veterans Affairs New York Harbor Healthcare System, 423 East 23rd Street, Room 6001W, New York, NY 10010, USA. Email: Zhiheng.pei@med.nyu.edu.

Submitted Jul 30, 2015. Accepted for publication Aug 03, 2015.

doi: 10.3978/j.issn.2305-5839.2015.08.07


Recent reports on microbiome leading to or in association with cancer have surfaced in the medical science field. The results may impact clinical management as new concepts may provide a glimpse of a new world for cancer diagnosis, therapy and prevention. There will be profound implications for the discipline of medicine and oncology and for how laboratory diagnosticians relate to medicine as a whole. This editorial will provide a succinct, but challenging, analysis from a major article on the subject of cancer and microbiome, and how we anticipate the field of medical oncology will change during the next 5 to 10 years. In the Science publication of April 2015, Garrett highlights several mechanisms through which microbes and microbiota contribute to the development of cancer, whether by enhancing or diminishing a host’s risk. The mechanisms fall into three categories: (I) modifying the balance of host cell proliferation and death; (II) piloting the function of the immune system; and (III) affecting the breakdown of host-generated factors, ingested food staples, and pharmaceuticals (1).

The influence of the host’s microbiota on cancer susceptibility has been widely studied recently. Garrett eloquently strengthened the evidence that microbes and microbiota contribute to the development and progression of cancer, and the host’s response to therapy (1). Of note, with respect to the millions of microbes living on earth, only ten are designated by the International Agency for Cancer Research (IACR) as carcinogenic to humans. However, there is speculation in regards to the implication of other microbes in carcinogenesis in mouse models and possibly humans (2,3).

There is a body of evidence that several bacteria can influence cancer risk via interfering with the β-catenin signaling (4). For example, oncogenic type 1 strains of Helicobacter pylori express the protein CagA, which abnormally modulates β-catenin to drive gastric cancer. Fusobacterium nucleatum that has been implicated in colorectal adenomas and adenocarcinomas through the FadA also promotes the activation of β-catenin. Additionally, enterotoxigenic Bacteroides fragilis that is augmented in some human colorectal cancers and Salmonella typhi strains that have been associated with hepatobiliary cancers, promote activation of the β-catenin signaling via Btf and AvrA, respectively (1,5-7).

Carcinogenesis may result from the combination of persistent barrier breach along with a failure to restore homeostasis. Mucosal surfaces are susceptible to this barrier breach by way of constant environmental insults and a lack of homeostasis, altering host-microbial symbiosis. As a result, microbiota may alter the life cycle of a host cell, interrupt the function of the immune system, and impact the host metabolism (1).

Bacteria can damage the host DNA directly by genotoxins and indirectly by bacterium-induced/host-produced inflammatory mediators. For example, colibactin, a polyketide-peptide genotoxin encoded by pks island in Escherichia coli causes DNA damage via crosslinking duplex DNA. Although not proven in humans, colibactin-expressing E. coli has been found to enhance intestinal tumorigenesis in mice and has garnered interest in the role it plays in colorectal carcinogenesis. Conversely, E. coli and Salmonella spp. can utilize reactive oxygen and nitrogen species produced in inflammation as nutrients to modulate the chronic inflammatory reactions as a means to enhance cancer growth and spread (7,8).

To advance our understanding of the role of microbiota in tumorigenesis, it is essential to comprehend both the beneficial and harmful effects of microbial metabolites. An illustration of the beneficial metabolites is short chain fat acids such as acetic, propionic, and butyric acids, produced by the intestinal fermentation of dietary fiber by members of the colonic microbiota (9). These fatty-acids employ their anti-inflammatory effects on myeloid cells and colonic regulatory T cells, reducing the cancer risk (9). The effects of short chain fatty acids are conducted by triggering a family of the cellular receptors, e.g., Niacr1/Gpr109a, Gpr43, Gpr41, or Olfr78. For instance, Gpr109a, expressed by both intestinal myeloid and epithelial cells, is a receptor for niacin and butyrate that performs a vital function in facilitating the effects of dietary fiber on the microbiota of the colon. Activation of Gpr109a by butyrate results in anti-inflammatory host feedbacks in myeloid cells that lead to regulatory T cell generation, and loss of Gpr109a predisposes to colitis-associated colorectal cancer (1,9). One of the offenders is high saturated fat intake that heightens cancer risk for reasons not yet fully understood. One theory views obesity as an inflammatory condition in line with the conventional wisdom that inflammation enhances cancer risk (9). A binding trio that comprises obesity, the microbiota and inflammation powers carcinogenesis; a concept that is corroborated by recently published data (1,10). Another relevant theory that has been investigated by numerous studies links a high fat diet to cancer risk through the bile acid pathway. Succinctly, high fat food increases bile acid secretion into the digestive tract. Secondary bile acids, converted only by gut bacteria, can accrue to high levels in the gut and may contribute to the pathogenesis of cancer of the laryngopharyngeal tract, esophagus, stomach, pancreas, the small intestine and the colon (11).

With the widening acceptance of gut microbiota function in drug metabolism, influencing toxicity and efficacy, there is interest in the microbiota’s modulation of chemotherapy toxicity and efficacy. Conceptually, the cause and effect relationship between gut microbiota and medications has been established. Medications (i.e., irinotecan, oxaliplatin, and cyclophosphamide) might have an impact in the gut microbiota which can also influence the effectiveness of chemotherapy (1,12). Henceforward, studies defining the response of gut microbiota to chemotherapy and microbiome scrutiny in patients with and at risk for cancer will be judicious to comprehend the utility of microbiota as an adjuvant therapy that augments effectiveness or mitigates toxicity of chemotherapies.

Another therapeutic modality that has gained attention in the combat of cancer is immunotherapy in the form of cytokine and vaccine therapy. In light of the intermingled nature of the microbiota and the immune system, it is conceivable that the microbiota influence a host’s responsiveness to immunotherapy. In truth, tumors such as melanoma, bladder, renal, and lung cancer have shown response to immunotherapy (1,13). Nonetheless, the same response has not been observed in colon cancer, intensifying curiosity in how the microbiota manipulate immunotherapy’s efficacy. It is irrefutable that bacteria may trigger the immune system to attack and destroy cancer cells. The Bacillus Calmette-Guerin (BCG), a perfect embodiment of this theory, is often administered in the form of a live vaccine used for the treatment of urothelial carcinoma that is not invasive into the muscle. The bacteria administered into the bladder by way of the BCG vaccine provokes an inflammatory reaction that ignites an antitumor immune response (1,14).

Microbiota studies in cancer remain at an early stage. In recent years, breathtaking advances in understanding the role of microbiota in cancer susceptibility have occurred at many levels. The pace of change is dizzying, both in numbers of studies and in the complexity of results. Given that many of the studies were performed in animal models, attention should be paid to their relevance to human cancers. The true pathophysiologic mechanisms related to microbes and innate and adaptive immune responses to tumors, as well as the repercussions on cancer progression and whether tumors subsequently become resistant or susceptible to different anticancer therapeutic regiments still are under investigation. It is conceivable to envision that within the next decade or so the identification of key contributors to microbiota-driven carcinogenesis will be unraveled facilitating tailored cancer therapeutic and preventive approaches.


Acknowledgements

Funding: This work was supported in part by grants U01CA182370, UH3CA140233, R03CA159414, and R01CA159036 from the National Cancer Institute and NIH Human Microbiome Project and by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development.


Footnote

Provenance: This is a Guest Editorial commissioned by the Section Editor Xiaozheng Kang, MD (Department of Thoracic Surgery, Beijing Cancer Hospital, Peking University, Beijing, China).

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Garrett WS. Cancer and the microbiota. Science 2015;348:80-6. [PubMed]
  2. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15. [PubMed]
  3. Kallmeyer J, Pockalny R, Adhikari RR, et al. Global distribution of microbial abundance and biomass in subseafloor sediment. Proc Natl Acad Sci U S A 2012;109:16213-6. [PubMed]
  4. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012;149:1192-205. [PubMed]
  5. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8. [PubMed]
  6. Lu R, Wu S, Zhang YG, et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis 2014;3:e105. [PubMed]
  7. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004;4:695-706. [PubMed]
  8. Arthur JC, Perez-Chanona E, Mühlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-3. [PubMed]
  9. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009;461:1282-6. [PubMed]
  10. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-4. [PubMed]
  11. Bernstein H, Bernstein C, Payne CM, et al. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 2005;589:47-65. [PubMed]
  12. Roberts AB, Wallace BD, Venkatesh MK, et al. Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 2013;84:208-17. [PubMed]
  13. Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 2013;6:1041-53. [PubMed]
  14. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol 2014;11:153-62. [PubMed]
Cite this article as: Neto AG, Bradshaw AD, Pei Z. Microbiome, a new dimension in cancer research. Ann Transl Med 2015;3(16):229. doi: 10.3978/j.issn.2305-5839.2015.08.07